Novo Nordisk A/S (NOVC.DE) XETRA
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Novo Nordisk A/S
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
59337
First IPO Date
June 07, 2001
Key Executives
| Name | Title | Pay | Year Born |
| Lars Fruergaard Jorgensen | Pres, Chief Executive Officer & Member of Management Board | 4.61M | 1966 |
| Martin Holst Lange | Executive Vice President of Devel. & Member of the Management Board | 1.74M | 1970 |
| Marcus Schindler | EVice President of Research & Early Devel., Chief Scientific Officer & Member of the Management Board | 1.74M | 1966 |
| Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporation Affairs and Member of the Management Board | 1.8M | 1972 |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | 1.83M | 1971 |
| Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board | 1.84M | 1970 |
| Douglas J. Langa | Executive Vice President of North America Operations & Member of Management Board | 0 | 1966 |
| Ludovic Helfgott | Executive Vice President, Head of Rare Disease & Member of Management Board | 0 | 1974 |
| Maziar Mike Doustdar | Executive Vice President of International Operations & Member of the Management Board | 0 | 1970 |
| Tania Sabroe | Executive Vice President of Global People & Organisation and Member of Management Board | 0 | N/A |
Description
Novo Nordisk A/S is a global healthcare enterprise that specializes in the discovery, development, production, and worldwide distribution of a comprehensive range of pharmaceutical products. The company's operations are structured around two core segments: diabetes and obesity care, and biopharmaceuticals. Within its diabetes and obesity portfolio, Novo Nordisk provides insulin products, GLP-1 receptor agonists, other protein-based medications such as glucagon, oral anti-diabetic treatments, and related drug delivery systems including needles. The biopharmaceuticals division focuses on therapeutic solutions for areas like hemophilia, growth hormone deficiencies, and hormone replacement. Prominent offerings include the obesity treatment Saxenda, alongside a suite of well-known brands such as NovoLog, NovoMix, NovoSeven, Norditropin, and Vagifem. As of December 2016, its products were available in over 180 countries, with commercial activities overseen by its North America and International Operations units.
